Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Endocrine therapies targeting estrogen signaling, such as tamoxifen, have significantly improved management of estrogen receptor alpha (ERα)‐positive breast cancers. However, their efficacy is limited by intrinsic and acquired resistance to treatment, and there is currently no predictive marker of response to these anti‐estrogens to guide treatment...
Alternative Titles
Full title
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_26bc168fc37e4a74ac05932309583845
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_26bc168fc37e4a74ac05932309583845
Other Identifiers
ISSN
1757-4676
E-ISSN
1757-4684
DOI
10.15252/emmm.202217248
